Transgene update from the previously mentioned ESMO congress (Madrid):
* Presents additional positive clinical data from phase 2b part of time trial with TG4010 at European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain
* Announces statistically significant difference in progression-free survival continuing to be seen in non-squamous patient population
* Announces promising overall survival data, notably in subgroups of interest for the upcoming phase 3 trial
http://www.reuters.com/article/2014/09/29/transgene-brief-idUSFWN0RR00R20140929
Transgene update from the previously mentioned ESMO congress...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.002(7.69%) |
Mkt cap ! $48.11M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.8¢ | 2.7¢ | $44.61K | 1.648M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 579398 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 2318208 | 1 |
View Market Depth
| Last trade - 15.52pm 29/07/2025 (20 minute delay) ? |
| VHL (ASX) Chart |